Patents by Inventor David Chiswell

David Chiswell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070148774
    Abstract: A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA.
    Type: Application
    Filed: November 1, 2006
    Publication date: June 28, 2007
    Applicants: MEDICAL RESEARCH COUNCIL, CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED
    Inventors: John McCafferty, Anthony Pope, Kevin Johnson, Hendricus Mattheus Hoogenboom, Andrew Griffiths, Ronald Jackson, Kasper Holliger, James Marks, Timothy Clackson, David Chiswell, Gregory Winter, Timothy Bonnert
  • Patent number: 5855885
    Abstract: Disclosed and claimed are methods for producing catalytic antibodies, including human catalytic antibodies, from bacteriophage. The methods require the cloning, selection, screening, and isolation of catalytic antibodies. Also disclosed and claimed are the products themselves, the catalytic antibodies, made from the phage technology. In addition, catalytic antibodies produced from the phage technology and useful in prodrug activation are disclosed and claimed. And finally, the invention also understands the production of catalytic antibodies to phosphonates.
    Type: Grant
    Filed: July 14, 1994
    Date of Patent: January 5, 1999
    Inventors: Rodger Smith, John McCafferty, David Chiswell, Michael J. Darsley, Kevin Fitzgerald, John H. Kenten, Mark T. Martin, Richard C. Titmas, Richard O. Williams